One of the miR-1253 targets in the inhibition of lung cancer development is neuro-oncological ventral antigens 2 (NOVA2) (Liu et al., 2021[63]), which plays a co and post-transcriptional splicing role in the process of pre-mRNA to mRNA transformation and also participates in the development of neural components and angiogenesis (Angiolini et al., 2019[4]; Mattioli et al., 2020[71]). The gene discussed is NOVA2; the disease is lung carcinoma.